Lung Cancer Online
Home Care Support Info Treatment Effects Tests Surviving Sites MedLit

 home > treatment > agents & regimens > erbitux

Erbitux (IMC-C225 or cetuximab) : ImClone/Bristol Myers Squibb : Monoclonal antibody to EGFR

Phase II Study of Cetuximab in Combination with Docetaxel in Chemotherapy Refractory/Resistant Patients with NSCLC (ASCO)
Abstract of a study presented at the 2003 ASCO annual meeting that found cetuximab in combination is well tolerated and the response rate suggests clinical activity in the second-line setting. Final analysis regarding duration of response and survival data is ongoing. [6/03]

Erbitux (IMC-C225) (ImClone Systems)
Describes IMC-C225 and how it works - in conjunction with chemotherapy or radiation - to treat cancer. Discusses current trials and previous trial results.

Erbitux (cetuximab) Receives FDA Approval to Treat Colorectal Cancer (Doctor's Guide)
Press release announcing FDA approval of Erbitux (cetuximab) injection for treatment of some patients with colorectal cancer. [2/04]

Erbitux (cetuximab) - Recent MEDLINE Abstracts (PubMed)

Erbitux (cetuximab) - Clinical Trials (ClinicalTrials.gov)


 

Feedback / Queries Disclaimer Advocacy - You Can Help

Copyright © 1999-2006, Lung Cancer Online Foundation
Last modified: 18-Feb-2009
Karen Parles, MLS Editor